FundCanna’s $60M Move + The Rise Of Pharma-Grade CBD
In the latest episode of Trade To Black presented by Flowhub, Shadd Dales and Anthony Varrell talk with FundCanna CEO Adam Stettner who announced a massive new institutional credit facility worth up to $60m from a global investment firm managing roughly $40 billion in assets. Trade To Black also continues its Vantage Standard series presented by Vantage Hemp with Deepank Utkhede, COO & Chief Process Biochemist at Vantage Hemp, and Christian Santi, Director of Sales at Vantage Hemp. The gap between standard CBD companies and businesses preparing for pharmaceutical-grade cannabinoid markets is extremely wide. We find out the reasons why.
In the news, fallout continues from Virginia Governor Abigail Spanberger’s veto of the state’s adult use cannabis bill. A report from Marijuana Moment says that the Cannabis Small Business Association, alongside Total Wine and Spirits, had reportedly urged the governor to reject the legislation. We’ll share our thoughts.
Adam Stettner, CEO of FundCanna, joined to detail his company’s newly secured $60m senior credit facility backed by a large institutional investor — a milestone he described as a first of its kind for the cannabis lending space. Stettner explained that the institution, a $40 billion fund, was not a cannabis-specific investor but rather a traditional capital source that assessed FundCanna’s underwriting discipline, compliance record, and track record before committing.
Stettner projected that FundCanna could deploy hundreds of millions of dollars over the next three years as institutional curiosity about the space continues to replace what he described as years of outright fear.
We explore Vantage Hemp with the podcast’s weekly Vantage Standard series, speaking with Christian Santi, Director of Sales, and Deepank Utkhede, Chief Operating Officer and Chief Process Biochemist. Both walked listeners through the pharmaceutical-grade cannabinoid manufacturing facility Vantage Hemp operates in Beardsley, Colorado.
From FDA Drug Master Files and global GMP certifications to clinical trial readiness and healthcare integration, Vantage is positioning itself very differently than most of the industry. Be sure to tune in for the interview.
